Amarin reported $473.69M in Equity Capital and Reserves for its fiscal quarter ending in March of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amarin USD 473.69M 12.49M Mar/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
DBV Technologies USD 86.22M 83.35M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Halozyme Therapeutics USD 332.75M 149.52M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025